Analgesics currently available for the treatment of pain following ophthalmic surgery or injury are limited by transient effectiveness and undesirable or adverse side effects. The cornea is primarily innervated by small-diameter C-fiber sensory neurons expressing TRPV1 (transient receptor potential channel, subfamily V, member 1), a sodium/calcium cation channel expressed abundantly by nociceptive neurons and consequently a target for pain control. Resiniferatoxin (RTX), a potent TRPV1 agonist, produces transient analgesia when injected peripherally by inactivating TRPV1-expressing nerve terminals through excessive calcium influx. The aim of the present study was to evaluate topical RTX as a corneal analgesic. In rat cornea, a single application of RTX dose dependently eliminated or reduced the capsaicin eye wipe response for 3-5 days, with normal nociceptive responses returning by 5-7 days. RTX alone produced a brief but intense noxious response, similar to capsaicin, necessitating pretreatment of the cornea with a local anesthetic. Topical lidocaine, applied prior to RTX, blocks acute nociceptive responses to RTX without impairing the subsequent analgesic effect. Importantly, RTX analgesia (a) did not impair epithelial wound healing, (b) left the blink reflex intact and (c) occurred without detectable histological damage to the cornea. Immunohistochemistry showed that loss of CGRP immunoreactivity, a surrogate marker for TRPV1-expressing fibers, extended at least to the corneal-scleral boundary and displayed a progressive return, coincident with the return of capsaicin sensitivity. These data suggest that RTX may be a safe and effective treatment for post-operative or post-injury ophthalmic pain.
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Introduction
Safe, long-lasting pain relief following corneal abrasions, corneal ulcers or ophthalmic surgery is difficult to achieve with current analgesics. For example, although effective acutely, continuous topical use of local anesthetics can produce an increased incidence of infection and corneal scarring, as well as impair the blink reflex and other non-nociceptive sensations [16] . Alternative routes of administration such as peribulbar or retrobulbar injections have increased risk and are also limited by transient effectiveness [7] . The use of topical NSAIDs and acetominophen is constrained by their gradual onset and limited efficacy [7] , and the adverse side effects of systemic opioids are well known [31] . Postoperative pain remains not only a barrier to the widespread use of clinically effective ophthalmic surgical procedures, such as photorefractive keratectomy [22] , but also a burden to patients during the recovery period.
Resiniferatoxin (RTX) is an ultra-potent agonist of the vanilloid receptor 1, now termed the transient receptor potential cation channel, subfamily V, member 1 (TRPV1). TRPV1 is an ion channel permeable to sodium and calcium and highly expressed in nociceptive neurons responsive to noxious heat, various endogenous algesic ligands, and the vanilloid agonist capsaicin (CAP) found in hot peppers [4, 26, 29] . RTX strongly activates TRPV1 producing a large influx of calcium, resulting in calcium-induced cytotoxicity [9, 23] . Intrathecal or intraganglionic administration can delete TRPV1-expressing neurons or lesion the dorsal roots to permanently attenuate thermal inflammatory and cancer pain [3, 11, 27] . When administered peripherally, a single dose of RTX produces a longlasting but reversible analgesia by ablating nociceptive nerve terminals [11, 13, 21] . Previous studies have demonstrated that 100 ng RTX injected subcutaneously into the rat hind paw
